Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4167586 · 1 trial · 2 indications
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4167586 (Cohorts A1 to A6) | EXPERIMENTAL | LY4167586 administered subcutaneously (SC) |
| Placebo (Cohorts A1 to A6) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY4167586 (Cohort B) | EXPERIMENTAL | LY4167586 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4167586 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participant must be 21 for Singapore site * Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive * Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight chang...
LY4167586 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development, studied in participants with obesity or overweight who are otherwise healthy.
LY4167586 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY.
LY4167586 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently active but not recruiting participants.
LY4167586 is being studied in a Phase 1 clinical trial with the identifier NCT07225556. This trial is titled 'A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy' and is being conducted in the United States and Singapore.
Yes, the Phase 1 clinical trial of LY4167586 is randomized, double-blind, and placebo-controlled. The study enrolls 84 participants, including healthy volunteers, and is designed to evaluate the drug in individuals with overweight or obesity.